nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—breast cancer	0.229	1	CbGaD
Lurasidone—CYP3A4—Exemestane—breast cancer	0.0502	0.133	CbGbCtD
Lurasidone—CYP3A4—Letrozole—breast cancer	0.0427	0.113	CbGbCtD
Lurasidone—CYP3A4—Anastrozole—breast cancer	0.038	0.101	CbGbCtD
Lurasidone—CYP3A4—Toremifene—breast cancer	0.0348	0.0921	CbGbCtD
Lurasidone—CYP3A4—Fulvestrant—breast cancer	0.0323	0.0856	CbGbCtD
Lurasidone—CYP3A4—Thiotepa—breast cancer	0.0288	0.0763	CbGbCtD
Lurasidone—CYP3A4—Ixabepilone—breast cancer	0.0264	0.0698	CbGbCtD
Lurasidone—CYP3A4—Lapatinib—breast cancer	0.0254	0.0672	CbGbCtD
Lurasidone—CYP3A4—Raloxifene—breast cancer	0.0192	0.0509	CbGbCtD
Lurasidone—CYP3A4—Vinorelbine—breast cancer	0.0141	0.0373	CbGbCtD
Lurasidone—CYP3A4—Tamoxifen—breast cancer	0.0127	0.0336	CbGbCtD
Lurasidone—CYP3A4—Mitoxantrone—breast cancer	0.0124	0.0328	CbGbCtD
Lurasidone—CYP3A4—Paclitaxel—breast cancer	0.00989	0.0262	CbGbCtD
Lurasidone—CYP3A4—Irinotecan—breast cancer	0.00976	0.0258	CbGbCtD
Lurasidone—CYP3A4—Vinblastine—breast cancer	0.00867	0.023	CbGbCtD
Lurasidone—CYP3A4—Docetaxel—breast cancer	0.00715	0.0189	CbGbCtD
Lurasidone—CYP3A4—Doxorubicin—breast cancer	0.00533	0.0141	CbGbCtD
Lurasidone—Ziprasidone—CYP2D6—breast cancer	0.000279	0.538	CrCbGaD
Lurasidone—Ziprasidone—CYP3A4—breast cancer	0.00024	0.462	CrCbGaD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.63e-05	0.000283	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—breast cancer	8.56e-05	0.000281	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—breast cancer	8.55e-05	0.000281	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—breast cancer	8.55e-05	0.000281	CcSEcCtD
Lurasidone—Decreased appetite—Paclitaxel—breast cancer	8.54e-05	0.00028	CcSEcCtD
Lurasidone—Hypertension—Capecitabine—breast cancer	8.53e-05	0.00028	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—breast cancer	8.5e-05	0.000279	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Paclitaxel—breast cancer	8.49e-05	0.000279	CcSEcCtD
Lurasidone—Fatigue—Paclitaxel—breast cancer	8.47e-05	0.000278	CcSEcCtD
Lurasidone—Asthenia—Gemcitabine—breast cancer	8.42e-05	0.000277	CcSEcCtD
Lurasidone—Myalgia—Capecitabine—breast cancer	8.41e-05	0.000276	CcSEcCtD
Lurasidone—Anxiety—Capecitabine—breast cancer	8.38e-05	0.000275	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	8.36e-05	0.000274	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—breast cancer	8.35e-05	0.000274	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—breast cancer	8.33e-05	0.000274	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—breast cancer	8.32e-05	0.000273	CcSEcCtD
Lurasidone—Pruritus—Gemcitabine—breast cancer	8.31e-05	0.000273	CcSEcCtD
Lurasidone—Nausea—Thiotepa—breast cancer	8.29e-05	0.000272	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—breast cancer	8.28e-05	0.000272	CcSEcCtD
Lurasidone—Infection—Docetaxel—breast cancer	8.28e-05	0.000272	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—breast cancer	8.25e-05	0.000271	CcSEcCtD
Lurasidone—Diarrhoea—Irinotecan—breast cancer	8.25e-05	0.000271	CcSEcCtD
Lurasidone—Diarrhoea—Mitoxantrone—breast cancer	8.25e-05	0.000271	CcSEcCtD
Lurasidone—Dry mouth—Capecitabine—breast cancer	8.23e-05	0.00027	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—breast cancer	8.22e-05	0.00027	CcSEcCtD
Lurasidone—Shock—Docetaxel—breast cancer	8.2e-05	0.000269	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—breast cancer	8.17e-05	0.000268	CcSEcCtD
Lurasidone—Pruritus—Fluorouracil—breast cancer	8.17e-05	0.000268	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—breast cancer	8.15e-05	0.000268	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—breast cancer	8.15e-05	0.000268	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—breast cancer	8.13e-05	0.000267	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—breast cancer	8.09e-05	0.000266	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—breast cancer	8.05e-05	0.000264	CcSEcCtD
Lurasidone—Gastrointestinal pain—Paclitaxel—breast cancer	8.04e-05	0.000264	CcSEcCtD
Lurasidone—Diarrhoea—Gemcitabine—breast cancer	8.03e-05	0.000264	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—breast cancer	8.01e-05	0.000263	CcSEcCtD
Lurasidone—Infection—Capecitabine—breast cancer	8.01e-05	0.000263	CcSEcCtD
Lurasidone—Dizziness—Irinotecan—breast cancer	7.97e-05	0.000262	CcSEcCtD
Lurasidone—Shock—Capecitabine—breast cancer	7.94e-05	0.000261	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—breast cancer	7.92e-05	0.00026	CcSEcCtD
Lurasidone—Nervous system disorder—Capecitabine—breast cancer	7.91e-05	0.00026	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—breast cancer	7.9e-05	0.000259	CcSEcCtD
Lurasidone—Diarrhoea—Fluorouracil—breast cancer	7.9e-05	0.000259	CcSEcCtD
Lurasidone—Tachycardia—Capecitabine—breast cancer	7.87e-05	0.000258	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—breast cancer	7.84e-05	0.000258	CcSEcCtD
Lurasidone—Skin disorder—Capecitabine—breast cancer	7.83e-05	0.000257	CcSEcCtD
Lurasidone—ADRA2C—nipple—breast cancer	7.83e-05	0.0624	CbGeAlD
Lurasidone—Urinary tract disorder—Epirubicin—breast cancer	7.81e-05	0.000256	CcSEcCtD
Lurasidone—Hyperhidrosis—Capecitabine—breast cancer	7.8e-05	0.000256	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—breast cancer	7.78e-05	0.000256	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—breast cancer	7.77e-05	0.000255	CcSEcCtD
Lurasidone—Abdominal pain—Paclitaxel—breast cancer	7.77e-05	0.000255	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—breast cancer	7.75e-05	0.000255	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—breast cancer	7.71e-05	0.000253	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—breast cancer	7.67e-05	0.000252	CcSEcCtD
Lurasidone—Vomiting—Irinotecan—breast cancer	7.66e-05	0.000252	CcSEcCtD
Lurasidone—Vomiting—Mitoxantrone—breast cancer	7.66e-05	0.000252	CcSEcCtD
Lurasidone—Dizziness—Fluorouracil—breast cancer	7.63e-05	0.000251	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—breast cancer	7.61e-05	0.00025	CcSEcCtD
Lurasidone—Rash—Irinotecan—breast cancer	7.6e-05	0.000249	CcSEcCtD
Lurasidone—Rash—Mitoxantrone—breast cancer	7.6e-05	0.000249	CcSEcCtD
Lurasidone—Dermatitis—Mitoxantrone—breast cancer	7.59e-05	0.000249	CcSEcCtD
Lurasidone—Dermatitis—Irinotecan—breast cancer	7.59e-05	0.000249	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—breast cancer	7.59e-05	0.000249	CcSEcCtD
Lurasidone—Hypotension—Capecitabine—breast cancer	7.54e-05	0.000247	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—breast cancer	7.53e-05	0.000247	CcSEcCtD
Lurasidone—Vomiting—Gemcitabine—breast cancer	7.46e-05	0.000245	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—breast cancer	7.45e-05	0.000245	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—breast cancer	7.43e-05	0.000244	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—breast cancer	7.41e-05	0.000243	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—breast cancer	7.4e-05	0.000243	CcSEcCtD
Lurasidone—Rash—Gemcitabine—breast cancer	7.4e-05	0.000243	CcSEcCtD
Lurasidone—Dermatitis—Gemcitabine—breast cancer	7.4e-05	0.000243	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—breast cancer	7.39e-05	0.000243	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—breast cancer	7.36e-05	0.000242	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Capecitabine—breast cancer	7.35e-05	0.000241	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—breast cancer	7.34e-05	0.000241	CcSEcCtD
Lurasidone—Vomiting—Fluorouracil—breast cancer	7.34e-05	0.000241	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—breast cancer	7.33e-05	0.000241	CcSEcCtD
Lurasidone—Insomnia—Capecitabine—breast cancer	7.3e-05	0.000239	CcSEcCtD
Lurasidone—Rash—Fluorouracil—breast cancer	7.28e-05	0.000239	CcSEcCtD
Lurasidone—Dermatitis—Fluorouracil—breast cancer	7.27e-05	0.000239	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—breast cancer	7.24e-05	0.000238	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—breast cancer	7.23e-05	0.000237	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—breast cancer	7.19e-05	0.000236	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—breast cancer	7.19e-05	0.000236	CcSEcCtD
Lurasidone—Dyspnoea—Capecitabine—breast cancer	7.19e-05	0.000236	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—breast cancer	7.18e-05	0.000236	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—breast cancer	7.18e-05	0.000236	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—breast cancer	7.17e-05	0.000236	CcSEcCtD
Lurasidone—Nausea—Mitoxantrone—breast cancer	7.16e-05	0.000235	CcSEcCtD
Lurasidone—Nausea—Irinotecan—breast cancer	7.16e-05	0.000235	CcSEcCtD
Lurasidone—Back pain—Methotrexate—breast cancer	7.12e-05	0.000234	CcSEcCtD
Lurasidone—Dyspepsia—Capecitabine—breast cancer	7.1e-05	0.000233	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—breast cancer	7.07e-05	0.000232	CcSEcCtD
Lurasidone—Asthenia—Paclitaxel—breast cancer	7.05e-05	0.000232	CcSEcCtD
Lurasidone—Decreased appetite—Capecitabine—breast cancer	7.01e-05	0.00023	CcSEcCtD
Lurasidone—Nausea—Gemcitabine—breast cancer	6.97e-05	0.000229	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Capecitabine—breast cancer	6.96e-05	0.000229	CcSEcCtD
Lurasidone—Fatigue—Capecitabine—breast cancer	6.95e-05	0.000228	CcSEcCtD
Lurasidone—Pruritus—Paclitaxel—breast cancer	6.95e-05	0.000228	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—breast cancer	6.93e-05	0.000228	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—breast cancer	6.93e-05	0.000227	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—breast cancer	6.89e-05	0.000226	CcSEcCtD
Lurasidone—Nausea—Fluorouracil—breast cancer	6.86e-05	0.000225	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—breast cancer	6.84e-05	0.000225	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—breast cancer	6.81e-05	0.000224	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—breast cancer	6.8e-05	0.000223	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—breast cancer	6.79e-05	0.000223	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—breast cancer	6.78e-05	0.000223	CcSEcCtD
Lurasidone—Diarrhoea—Paclitaxel—breast cancer	6.72e-05	0.000221	CcSEcCtD
Lurasidone—Back pain—Epirubicin—breast cancer	6.66e-05	0.000219	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—breast cancer	6.64e-05	0.000218	CcSEcCtD
Lurasidone—Malaise—Methotrexate—breast cancer	6.63e-05	0.000218	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—breast cancer	6.62e-05	0.000217	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—breast cancer	6.61e-05	0.000217	CcSEcCtD
Lurasidone—Gastrointestinal pain—Capecitabine—breast cancer	6.6e-05	0.000217	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—breast cancer	6.59e-05	0.000216	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—breast cancer	6.59e-05	0.000216	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—breast cancer	6.54e-05	0.000215	CcSEcCtD
Lurasidone—Dizziness—Paclitaxel—breast cancer	6.5e-05	0.000213	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—breast cancer	6.49e-05	0.000213	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—breast cancer	6.41e-05	0.00021	CcSEcCtD
Lurasidone—Abdominal pain—Capecitabine—breast cancer	6.38e-05	0.000209	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—breast cancer	6.37e-05	0.000209	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—breast cancer	6.37e-05	0.000209	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—breast cancer	6.36e-05	0.000209	CcSEcCtD
Lurasidone—Agitation—Epirubicin—breast cancer	6.33e-05	0.000208	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—breast cancer	6.28e-05	0.000206	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—breast cancer	6.26e-05	0.000206	CcSEcCtD
Lurasidone—Vomiting—Paclitaxel—breast cancer	6.25e-05	0.000205	CcSEcCtD
Lurasidone—ADRA2A—nipple—breast cancer	6.25e-05	0.0498	CbGeAlD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.22e-05	0.000204	CcSEcCtD
Lurasidone—Malaise—Epirubicin—breast cancer	6.21e-05	0.000204	CcSEcCtD
Lurasidone—Rash—Paclitaxel—breast cancer	6.2e-05	0.000203	CcSEcCtD
Lurasidone—Dermatitis—Paclitaxel—breast cancer	6.19e-05	0.000203	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—breast cancer	6.19e-05	0.000203	CcSEcCtD
Lurasidone—Syncope—Epirubicin—breast cancer	6.17e-05	0.000203	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—breast cancer	6.16e-05	0.000202	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—breast cancer	6.16e-05	0.000202	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—breast cancer	6.12e-05	0.000201	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—breast cancer	6.05e-05	0.000199	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—breast cancer	6e-05	0.000197	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—breast cancer	5.98e-05	0.000196	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—breast cancer	5.97e-05	0.000196	CcSEcCtD
Lurasidone—Infection—Methotrexate—breast cancer	5.97e-05	0.000196	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—breast cancer	5.94e-05	0.000195	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—breast cancer	5.89e-05	0.000193	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—breast cancer	5.89e-05	0.000193	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—breast cancer	5.89e-05	0.000193	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—breast cancer	5.86e-05	0.000192	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—breast cancer	5.85e-05	0.000192	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—breast cancer	5.84e-05	0.000192	CcSEcCtD
Lurasidone—Nausea—Paclitaxel—breast cancer	5.84e-05	0.000192	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—breast cancer	5.83e-05	0.000191	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.82e-05	0.000191	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—breast cancer	5.8e-05	0.000191	CcSEcCtD
Lurasidone—Asthenia—Capecitabine—breast cancer	5.79e-05	0.00019	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—breast cancer	5.74e-05	0.000189	CcSEcCtD
Lurasidone—HTR7—epithelium—breast cancer	5.73e-05	0.0457	CbGeAlD
Lurasidone—Dry mouth—Epirubicin—breast cancer	5.73e-05	0.000188	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—breast cancer	5.72e-05	0.000188	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—breast cancer	5.71e-05	0.000188	CcSEcCtD
Lurasidone—Pruritus—Capecitabine—breast cancer	5.71e-05	0.000187	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—breast cancer	5.7e-05	0.000187	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—breast cancer	5.7e-05	0.000187	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—breast cancer	5.61e-05	0.000184	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—breast cancer	5.6e-05	0.000184	CcSEcCtD
Lurasidone—Infection—Epirubicin—breast cancer	5.58e-05	0.000183	CcSEcCtD
Lurasidone—Shock—Epirubicin—breast cancer	5.53e-05	0.000181	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—breast cancer	5.52e-05	0.000181	CcSEcCtD
Lurasidone—Diarrhoea—Capecitabine—breast cancer	5.52e-05	0.000181	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—breast cancer	5.51e-05	0.000181	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—breast cancer	5.51e-05	0.000181	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—breast cancer	5.5e-05	0.000181	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—breast cancer	5.48e-05	0.00018	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—breast cancer	5.47e-05	0.00018	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—breast cancer	5.46e-05	0.000179	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—breast cancer	5.43e-05	0.000178	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—breast cancer	5.43e-05	0.000178	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—breast cancer	5.42e-05	0.000178	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—breast cancer	5.4e-05	0.000177	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.39e-05	0.000177	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—breast cancer	5.35e-05	0.000176	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—breast cancer	5.34e-05	0.000175	CcSEcCtD
Lurasidone—Dizziness—Capecitabine—breast cancer	5.33e-05	0.000175	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—breast cancer	5.3e-05	0.000174	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—breast cancer	5.3e-05	0.000174	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—breast cancer	5.29e-05	0.000174	CcSEcCtD
Lurasidone—Rash—Docetaxel—breast cancer	5.25e-05	0.000172	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—breast cancer	5.25e-05	0.000172	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—breast cancer	5.25e-05	0.000172	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—breast cancer	5.22e-05	0.000171	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—breast cancer	5.18e-05	0.00017	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—breast cancer	5.18e-05	0.00017	CcSEcCtD
Lurasidone—Infection—Doxorubicin—breast cancer	5.17e-05	0.00017	CcSEcCtD
Lurasidone—Vomiting—Capecitabine—breast cancer	5.13e-05	0.000168	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—breast cancer	5.12e-05	0.000168	CcSEcCtD
Lurasidone—Shock—Doxorubicin—breast cancer	5.12e-05	0.000168	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—breast cancer	5.1e-05	0.000167	CcSEcCtD
Lurasidone—Rash—Capecitabine—breast cancer	5.09e-05	0.000167	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—breast cancer	5.08e-05	0.000167	CcSEcCtD
Lurasidone—Dermatitis—Capecitabine—breast cancer	5.08e-05	0.000167	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—breast cancer	5.07e-05	0.000167	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—breast cancer	5.05e-05	0.000166	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—breast cancer	5.03e-05	0.000165	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—breast cancer	5.01e-05	0.000164	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—breast cancer	5e-05	0.000164	CcSEcCtD
Lurasidone—Nausea—Docetaxel—breast cancer	4.95e-05	0.000162	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—breast cancer	4.95e-05	0.000162	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—breast cancer	4.91e-05	0.000161	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—breast cancer	4.88e-05	0.00016	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—breast cancer	4.86e-05	0.000159	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—breast cancer	4.85e-05	0.000159	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—breast cancer	4.84e-05	0.000159	CcSEcCtD
Lurasidone—Nausea—Capecitabine—breast cancer	4.79e-05	0.000157	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—breast cancer	4.75e-05	0.000156	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.74e-05	0.000156	CcSEcCtD
Lurasidone—ADRA2C—endometrium—breast cancer	4.73e-05	0.0377	CbGeAlD
Lurasidone—Insomnia—Doxorubicin—breast cancer	4.7e-05	0.000154	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—breast cancer	4.64e-05	0.000152	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—breast cancer	4.62e-05	0.000152	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—breast cancer	4.59e-05	0.000151	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—breast cancer	4.58e-05	0.00015	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—breast cancer	4.52e-05	0.000148	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—breast cancer	4.49e-05	0.000147	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—breast cancer	4.48e-05	0.000147	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—breast cancer	4.44e-05	0.000146	CcSEcCtD
Lurasidone—DRD2—pituitary gland—breast cancer	4.4e-05	0.0351	CbGeAlD
Lurasidone—HTR2A—embryo—breast cancer	4.38e-05	0.0349	CbGeAlD
Lurasidone—ADRA2C—uterus—breast cancer	4.36e-05	0.0347	CbGeAlD
Lurasidone—HTR1A—adrenal gland—breast cancer	4.35e-05	0.0347	CbGeAlD
Lurasidone—Asthenia—Methotrexate—breast cancer	4.31e-05	0.000141	CcSEcCtD
Lurasidone—ADRA2C—pituitary gland—breast cancer	4.28e-05	0.0341	CbGeAlD
Lurasidone—HTR7—female reproductive system—breast cancer	4.26e-05	0.0339	CbGeAlD
Lurasidone—ADRA2C—adipose tissue—breast cancer	4.26e-05	0.0339	CbGeAlD
Lurasidone—Gastrointestinal pain—Doxorubicin—breast cancer	4.25e-05	0.00014	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—breast cancer	4.25e-05	0.000139	CcSEcCtD
Lurasidone—HTR7—adrenal gland—breast cancer	4.16e-05	0.0331	CbGeAlD
Lurasidone—Abdominal pain—Doxorubicin—breast cancer	4.11e-05	0.000135	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—breast cancer	4.11e-05	0.000135	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—breast cancer	4.03e-05	0.000132	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—breast cancer	3.98e-05	0.000131	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—breast cancer	3.97e-05	0.00013	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—breast cancer	3.84e-05	0.000126	CcSEcCtD
Lurasidone—ADRA2C—adrenal gland—breast cancer	3.82e-05	0.0304	CbGeAlD
Lurasidone—Vomiting—Methotrexate—breast cancer	3.82e-05	0.000125	CcSEcCtD
Lurasidone—Rash—Methotrexate—breast cancer	3.79e-05	0.000124	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—breast cancer	3.78e-05	0.000124	CcSEcCtD
Lurasidone—HTR1A—endocrine gland—breast cancer	3.77e-05	0.0301	CbGeAlD
Lurasidone—ADRA2A—endometrium—breast cancer	3.77e-05	0.03	CbGeAlD
Lurasidone—Asthenia—Doxorubicin—breast cancer	3.73e-05	0.000122	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—breast cancer	3.72e-05	0.000122	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—breast cancer	3.68e-05	0.000121	CcSEcCtD
Lurasidone—HTR7—endocrine gland—breast cancer	3.6e-05	0.0287	CbGeAlD
Lurasidone—HTR2A—epithelium—breast cancer	3.58e-05	0.0285	CbGeAlD
Lurasidone—Vomiting—Epirubicin—breast cancer	3.57e-05	0.000117	CcSEcCtD
Lurasidone—Nausea—Methotrexate—breast cancer	3.57e-05	0.000117	CcSEcCtD
Lurasidone—ADRA2C—female gonad—breast cancer	3.56e-05	0.0284	CbGeAlD
Lurasidone—Diarrhoea—Doxorubicin—breast cancer	3.56e-05	0.000117	CcSEcCtD
Lurasidone—Rash—Epirubicin—breast cancer	3.54e-05	0.000116	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—breast cancer	3.54e-05	0.000116	CcSEcCtD
Lurasidone—ADRA2A—uterus—breast cancer	3.48e-05	0.0277	CbGeAlD
Lurasidone—Dizziness—Doxorubicin—breast cancer	3.44e-05	0.000113	CcSEcCtD
Lurasidone—ADRA2A—pituitary gland—breast cancer	3.41e-05	0.0272	CbGeAlD
Lurasidone—DRD2—endocrine gland—breast cancer	3.41e-05	0.0272	CbGeAlD
Lurasidone—ADRA2A—adipose tissue—breast cancer	3.4e-05	0.0271	CbGeAlD
Lurasidone—Nausea—Epirubicin—breast cancer	3.34e-05	0.00011	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—breast cancer	3.31e-05	0.000109	CcSEcCtD
Lurasidone—Rash—Doxorubicin—breast cancer	3.28e-05	0.000108	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—breast cancer	3.28e-05	0.000108	CcSEcCtD
Lurasidone—ADRA2A—female reproductive system—breast cancer	3.12e-05	0.0249	CbGeAlD
Lurasidone—Nausea—Doxorubicin—breast cancer	3.09e-05	0.000101	CcSEcCtD
Lurasidone—ADRA2A—adrenal gland—breast cancer	3.05e-05	0.0243	CbGeAlD
Lurasidone—HTR2A—pituitary gland—breast cancer	2.9e-05	0.0231	CbGeAlD
Lurasidone—ADRA2A—female gonad—breast cancer	2.84e-05	0.0226	CbGeAlD
Lurasidone—HTR2A—female reproductive system—breast cancer	2.66e-05	0.0212	CbGeAlD
Lurasidone—ADRA2A—endocrine gland—breast cancer	2.64e-05	0.0211	CbGeAlD
Lurasidone—HTR2A—adrenal gland—breast cancer	2.59e-05	0.0207	CbGeAlD
Lurasidone—CYP3A4—female reproductive system—breast cancer	2.46e-05	0.0196	CbGeAlD
Lurasidone—ADRA2C—lymph node—breast cancer	2.29e-05	0.0182	CbGeAlD
Lurasidone—HTR2A—endocrine gland—breast cancer	2.25e-05	0.0179	CbGeAlD
Lurasidone—CYP3A4—endocrine gland—breast cancer	2.08e-05	0.0166	CbGeAlD
Lurasidone—ADRA2A—lymph node—breast cancer	1.83e-05	0.0146	CbGeAlD
Lurasidone—ADRA2A—Signaling Pathways—KIT—breast cancer	5.69e-06	6.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—breast cancer	5.69e-06	6.59e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RAF1—breast cancer	5.68e-06	6.58e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RELA—breast cancer	5.66e-06	6.55e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NOS3—breast cancer	5.65e-06	6.54e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2D6—breast cancer	5.63e-06	6.52e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGF—breast cancer	5.62e-06	6.51e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—breast cancer	5.62e-06	6.51e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—breast cancer	5.59e-06	6.47e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—breast cancer	5.55e-06	6.42e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MTOR—breast cancer	5.55e-06	6.42e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—breast cancer	5.55e-06	6.42e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	5.54e-06	6.41e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—breast cancer	5.53e-06	6.41e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOA2—breast cancer	5.53e-06	6.4e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK3—breast cancer	5.53e-06	6.4e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—breast cancer	5.53e-06	6.4e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MDM2—breast cancer	5.52e-06	6.39e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—breast cancer	5.5e-06	6.36e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RAF1—breast cancer	5.5e-06	6.36e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RELA—breast cancer	5.47e-06	6.34e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—breast cancer	5.47e-06	6.33e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	5.45e-06	6.31e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	5.44e-06	6.3e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—breast cancer	5.44e-06	6.3e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—breast cancer	5.44e-06	6.29e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—breast cancer	5.38e-06	6.23e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—breast cancer	5.37e-06	6.22e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	5.37e-06	6.21e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MTOR—breast cancer	5.37e-06	6.21e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—breast cancer	5.36e-06	6.21e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—FASN—breast cancer	5.36e-06	6.21e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—breast cancer	5.35e-06	6.19e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—BCHE—breast cancer	5.34e-06	6.18e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—breast cancer	5.33e-06	6.17e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—breast cancer	5.3e-06	6.13e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOS3—breast cancer	5.28e-06	6.11e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC5A5—breast cancer	5.27e-06	6.11e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—breast cancer	5.26e-06	6.09e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—breast cancer	5.21e-06	6.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IGF1—breast cancer	5.21e-06	6.03e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT2—breast cancer	5.21e-06	6.03e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1B—breast cancer	5.2e-06	6.03e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOS3—breast cancer	5.19e-06	6.01e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—breast cancer	5.18e-06	6e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—breast cancer	5.17e-06	5.98e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—breast cancer	5.16e-06	5.97e-05	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—breast cancer	5.15e-06	5.96e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—breast cancer	5.12e-06	5.93e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—breast cancer	5.1e-06	5.91e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—breast cancer	5.09e-06	5.9e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC2A1—breast cancer	5.09e-06	5.9e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NQO1—breast cancer	5.09e-06	5.9e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—breast cancer	5.07e-06	5.87e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	5.04e-06	5.83e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—breast cancer	5.03e-06	5.82e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MDM2—breast cancer	5.01e-06	5.79e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	5e-06	5.79e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RAF1—breast cancer	4.99e-06	5.77e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	4.98e-06	5.77e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—breast cancer	4.97e-06	5.75e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RELA—breast cancer	4.97e-06	5.75e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—breast cancer	4.97e-06	5.75e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JUN—breast cancer	4.95e-06	5.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	4.95e-06	5.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	4.95e-06	5.73e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	4.94e-06	5.72e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—breast cancer	4.94e-06	5.71e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—breast cancer	4.93e-06	5.71e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—breast cancer	4.93e-06	5.71e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MDM2—breast cancer	4.92e-06	5.7e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CTNNB1—breast cancer	4.92e-06	5.69e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RAF1—breast cancer	4.91e-06	5.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—breast cancer	4.9e-06	5.68e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—breast cancer	4.9e-06	5.67e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RELA—breast cancer	4.89e-06	5.66e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1B1—breast cancer	4.88e-06	5.65e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MTOR—breast cancer	4.87e-06	5.64e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—breast cancer	4.87e-06	5.64e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—breast cancer	4.86e-06	5.62e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—breast cancer	4.82e-06	5.58e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—breast cancer	4.8e-06	5.56e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—breast cancer	4.8e-06	5.56e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JUN—breast cancer	4.79e-06	5.55e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—breast cancer	4.79e-06	5.55e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MTOR—breast cancer	4.79e-06	5.55e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—breast cancer	4.79e-06	5.55e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HSP90AA1—breast cancer	4.79e-06	5.54e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	4.76e-06	5.51e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOS3—breast cancer	4.72e-06	5.47e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK8—breast cancer	4.69e-06	5.43e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—breast cancer	4.68e-06	5.42e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—breast cancer	4.68e-06	5.41e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—breast cancer	4.66e-06	5.4e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOA1—breast cancer	4.66e-06	5.39e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—breast cancer	4.65e-06	5.38e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	4.65e-06	5.38e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—breast cancer	4.64e-06	5.37e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—breast cancer	4.6e-06	5.33e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP19A1—breast cancer	4.59e-06	5.32e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—STK11—breast cancer	4.59e-06	5.32e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—breast cancer	4.57e-06	5.3e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1B—breast cancer	4.57e-06	5.29e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—breast cancer	4.56e-06	5.28e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK8—breast cancer	4.54e-06	5.25e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—breast cancer	4.52e-06	5.24e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—breast cancer	4.52e-06	5.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—breast cancer	4.5e-06	5.22e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	4.5e-06	5.21e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1B—breast cancer	4.5e-06	5.21e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MDM2—breast cancer	4.48e-06	5.19e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—breast cancer	4.48e-06	5.19e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—breast cancer	4.47e-06	5.18e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RAF1—breast cancer	4.46e-06	5.17e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—breast cancer	4.45e-06	5.15e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—breast cancer	4.45e-06	5.15e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RELA—breast cancer	4.45e-06	5.15e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SRC—breast cancer	4.44e-06	5.15e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—breast cancer	4.42e-06	5.11e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—breast cancer	4.41e-06	5.11e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—breast cancer	4.41e-06	5.1e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—breast cancer	4.4e-06	5.09e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—breast cancer	4.38e-06	5.07e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—breast cancer	4.36e-06	5.05e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	4.36e-06	5.05e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MTOR—breast cancer	4.36e-06	5.05e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JUN—breast cancer	4.35e-06	5.04e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—breast cancer	4.33e-06	5.01e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CTNNB1—breast cancer	4.32e-06	5e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SRC—breast cancer	4.3e-06	4.98e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—breast cancer	4.29e-06	4.97e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—breast cancer	4.29e-06	4.96e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JUN—breast cancer	4.28e-06	4.96e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—COMT—breast cancer	4.27e-06	4.94e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CTNNB1—breast cancer	4.25e-06	4.92e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—breast cancer	4.25e-06	4.92e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—breast cancer	4.23e-06	4.9e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—breast cancer	4.22e-06	4.89e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—breast cancer	4.22e-06	4.88e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—breast cancer	4.21e-06	4.87e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMOX1—breast cancer	4.19e-06	4.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—breast cancer	4.19e-06	4.85e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—breast cancer	4.19e-06	4.85e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ITPR1—breast cancer	4.18e-06	4.84e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—breast cancer	4.16e-06	4.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—breast cancer	4.16e-06	4.82e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—breast cancer	4.15e-06	4.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—breast cancer	4.15e-06	4.8e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—breast cancer	4.14e-06	4.79e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK8—breast cancer	4.12e-06	4.77e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—breast cancer	4.11e-06	4.75e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK3—breast cancer	4.09e-06	4.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	4.09e-06	4.74e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK8—breast cancer	4.05e-06	4.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	4.05e-06	4.69e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—breast cancer	4.04e-06	4.68e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—breast cancer	4.04e-06	4.68e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCB1—breast cancer	4.02e-06	4.66e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—breast cancer	4.01e-06	4.64e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—breast cancer	4e-06	4.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—breast cancer	3.98e-06	4.61e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—breast cancer	3.98e-06	4.61e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—breast cancer	3.97e-06	4.6e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK3—breast cancer	3.96e-06	4.59e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TYMS—breast cancer	3.95e-06	4.57e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—breast cancer	3.91e-06	4.53e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOR1—breast cancer	3.9e-06	4.52e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PLA2G4A—breast cancer	3.9e-06	4.52e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—breast cancer	3.9e-06	4.52e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—breast cancer	3.9e-06	4.52e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SRC—breast cancer	3.9e-06	4.52e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—breast cancer	3.9e-06	4.51e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JUN—breast cancer	3.89e-06	4.51e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	3.86e-06	4.47e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—breast cancer	3.85e-06	4.46e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—breast cancer	3.84e-06	4.45e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SRC—breast cancer	3.84e-06	4.45e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—breast cancer	3.8e-06	4.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—breast cancer	3.79e-06	4.39e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	3.78e-06	4.37e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—breast cancer	3.77e-06	4.36e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—breast cancer	3.77e-06	4.36e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—breast cancer	3.76e-06	4.36e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—breast cancer	3.74e-06	4.33e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GPX1—breast cancer	3.74e-06	4.33e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—breast cancer	3.73e-06	4.32e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—breast cancer	3.7e-06	4.29e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A1—breast cancer	3.7e-06	4.28e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK8—breast cancer	3.68e-06	4.27e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—breast cancer	3.68e-06	4.26e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—breast cancer	3.67e-06	4.25e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ERCC2—breast cancer	3.67e-06	4.25e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK3—breast cancer	3.6e-06	4.16e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—breast cancer	3.56e-06	4.12e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK3—breast cancer	3.54e-06	4.1e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—breast cancer	3.5e-06	4.05e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SRC—breast cancer	3.49e-06	4.04e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—breast cancer	3.49e-06	4.04e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—breast cancer	3.45e-06	3.99e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—breast cancer	3.44e-06	3.98e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—breast cancer	3.43e-06	3.97e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—breast cancer	3.42e-06	3.96e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—breast cancer	3.4e-06	3.94e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—breast cancer	3.38e-06	3.91e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—breast cancer	3.37e-06	3.9e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—breast cancer	3.37e-06	3.9e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	3.27e-06	3.79e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—breast cancer	3.27e-06	3.79e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—breast cancer	3.23e-06	3.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK3—breast cancer	3.22e-06	3.73e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—breast cancer	3.2e-06	3.7e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAV1—breast cancer	3.18e-06	3.68e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—breast cancer	3.18e-06	3.68e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—breast cancer	3.18e-06	3.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—breast cancer	3.16e-06	3.66e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—breast cancer	3.13e-06	3.62e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—breast cancer	3.13e-06	3.62e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—breast cancer	3.12e-06	3.62e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—breast cancer	3.06e-06	3.54e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—breast cancer	3.03e-06	3.5e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—breast cancer	2.99e-06	3.47e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—breast cancer	2.97e-06	3.44e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—breast cancer	2.92e-06	3.38e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—breast cancer	2.9e-06	3.36e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—breast cancer	2.9e-06	3.35e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—breast cancer	2.89e-06	3.35e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—breast cancer	2.87e-06	3.32e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—breast cancer	2.83e-06	3.27e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—breast cancer	2.76e-06	3.2e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—breast cancer	2.75e-06	3.18e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—breast cancer	2.7e-06	3.13e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—breast cancer	2.67e-06	3.09e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	2.66e-06	3.08e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—breast cancer	2.63e-06	3.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—breast cancer	2.6e-06	3.01e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—breast cancer	2.59e-06	2.99e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—breast cancer	2.57e-06	2.98e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—breast cancer	2.55e-06	2.95e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—breast cancer	2.52e-06	2.91e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.46e-06	2.85e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—breast cancer	2.43e-06	2.81e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NOS3—breast cancer	2.41e-06	2.79e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—breast cancer	2.39e-06	2.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—breast cancer	2.35e-06	2.72e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—breast cancer	2.22e-06	2.57e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—breast cancer	2.2e-06	2.55e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—breast cancer	2.17e-06	2.51e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—breast cancer	1.92e-06	2.22e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—breast cancer	1.35e-06	1.57e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—breast cancer	1.11e-06	1.28e-05	CbGpPWpGaD
